Nonalcoholic steatohepatitis
Authors:
- Jörn M. SchattenbergJSJörn M. Schattenberg
- Detlef SchuppanDSDetlef Schuppan
- 1 December 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 22 (6) , 479-488
Abstract
Nonalcoholic fatty liver (NAFL) and especially its inflammatory variant nonalcoholic steatohepatitis (NASH) have become a major challenge to healthcare systems worldwide because of the increasing prevalence of its major risk factors obesity and type 2 diabetes, which are closely linked to overeating, physical inactivity, and the metabolic syndrome. Between 10 and 20% of patients with NAFL develop NASH, which can progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The overall mortality in these patients is significantly increased because of both cardiovascular and liver-related complications. Sustained weight loss by diet and exercise, which is the most effective therapeutic measure, is only achieved by a minority of patients, having led to a great yet unmet need for medical therapies of NASH. Pharmacological therapies should target the underlying pathophysiology that involves insulin resistance, enhanced peripheral lipolysis and release of free fatty acids, oxidative stress, accumulation of toxic lipids, adipose tissue inflammation, sensitization of hepatocytes toward apoptotic cell death, and fibrogenesis. However, pharmacological therapy that is well tolerated, cost-effective, and poses an acceptable risk-to-benefit ratio has still to be identified. This review summarizes the current and promising treatment options and their implications for future research and clinical practice.Keywords
This publication has 89 references indexed in Scilit:
- Epigenetic codes of PPARγ in metabolic diseaseFEBS Letters, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Endocannabinoids in liver diseaseHepatology, 2010
- Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese AdultsJAMA, 2010
- High-Fructose, Medium Chain Trans Fat Diet Induces Liver Fibrosis and Elevates Plasma Coenzyme Q9 in a Novel Murine Model of Obesity and Nonalcoholic Steatohepatitis†Hepatology, 2010
- Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Health‐related fitness and physical activity in patients with nonalcoholic fatty liver disease†‡Hepatology, 2008
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005